
RedHill Biopharma (RDHL) Stock Forecast & Price Target
RedHill Biopharma (RDHL) Analyst Ratings
Based on 9 analyst ratings
Strong Buy
Strong Buy 89%
Buy 11%
Hold 0%
Sell 0%
Strong Sell 0%
RedHill Biopharma (RDHL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 89% of analysts recommend a Strong Buy, 11% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of RedHill Biopharma and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of RedHill Biopharma and is not a guaranteed prediction by Public.com or investment advice.
RedHill Biopharma (RDHL) Analyst Forecast & Price Prediction
Get the latest RedHill Biopharma (RDHL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in RedHill Biopharma (RDHL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About RedHill Biopharma (RDHL) Forecast
Analysts have given RedHill Biopharma (RDHL) a Strong Buy based on their latest research and market trends.
According to 9 analysts, RedHill Biopharma (RDHL) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $21.89, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $21.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.